Sun, May 19, 2013, 12:52 AM EDT - U.S. Markets closed
CIBC initiates VRTX as a "Sector Outperformer" and sets a $42 tgt, as they believe the co's lead drug, TVR, an antiviral drug for hepatitis C, has the potential to revolutionize the treatment paradigm for the disease.